INT343017

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.21
First Reported 2010
Last Reported 2010
Negated 1
Speculated 0
Reported most in Body
Documents 1
Total Number 4
Disease Relevance 2.39
Pain Relevance 0.16

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell differentiation (Azi1)
Azi1 (Mus musculus)
Pain Link Frequency Relevance Heat
abdominal pain 20 65.12 Quite High
imagery 24 59.40 Quite High
Bioavailability 8 42.72 Quite Low
Central nervous system 4 31.60 Quite Low
nud 16 5.00 Very Low Very Low Very Low
agonist 8 5.00 Very Low Very Low Very Low
Analgesic 4 5.00 Very Low Very Low Very Low
sSRI 4 5.00 Very Low Very Low Very Low
anesthesia 4 5.00 Very Low Very Low Very Low
Calcium channel 4 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Gastric Motility Disorder 140 100.00 Very High Very High Very High
Arrhythmia Under Development 12 91.64 High High
Dyskinesias 4 80.40 Quite High
Vomiting 32 70.40 Quite High
Diarrhoea 4 68.72 Quite High
Abdominal Pain 20 65.12 Quite High
Myocardial Infarction 20 55.96 Quite High
Cirrhosis 4 42.36 Quite Low
Lacerations 4 38.16 Quite Low
Umbilical Hernia 4 34.56 Quite Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This result supports the use of AZI as a viable alternative to ERY for treating GP, as well as findings from a previous study and case report suggesting a role for AZI in the treatment of GP.35,36 AZI could also be used during provocative testing with GES to evaluate response to this novel prokinetic that has never previously been used in the literature for such a purpose.
Positive_regulation (role) of AZI associated with gastric motility disorder
1) Confidence 0.21 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978393 Disease Relevance 0.78 Pain Relevance 0.06
This result supports the use of AZI as a viable alternative to ERY for treating GP, as well as findings from a previous study and case report suggesting a role for AZI in the treatment of GP.35,36 AZI could also be used during provocative testing with GES to evaluate response to this novel prokinetic that has never previously been used in the literature for such a purpose.
Positive_regulation (treatment) of AZI associated with gastric motility disorder
2) Confidence 0.21 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978393 Disease Relevance 0.78 Pain Relevance 0.07
In addition, in our extensive clinical experience with AZI, we have found AZI to be very effective for the symptomatic treatment of patients with GP in those who have failed on both metoclopramide and ERY (unpublished observations).
Positive_regulation (effective) of AZI associated with gastric motility disorder
3) Confidence 0.20 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978393 Disease Relevance 0.40 Pain Relevance 0.03
The study concluded that while AZI was not effective for secondary prevention of coronary events, no increased risk of cardiac events was observed in patients on AZI.39
Neg (not) Positive_regulation (effective) of AZI
4) Confidence 0.20 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978393 Disease Relevance 0.44 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox